Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt repayments

Daily Values

Growth Metrics

AbCellera Biologics (ABCL) Long-Term Debt Repayments (2020 - 2021)

AbCellera Biologics filings provide 2 years of Long-Term Debt Repayments readings, the most recent being $107000.0 for Q2 2021.

Quarterly Long-Term Debt Repayments rose 272.58% to $107000.0 in Q2 2021 from the year-ago period, while the trailing twelve-month figure was $1.8 million through Dec 2021, down 90.86% year-over-year, with the annual reading at $1.8 million for FY2021, 90.86% down from the prior year.
Long-Term Debt Repayments hit $107000.0 in Q2 2021 for AbCellera Biologics, down from $1.7 million in the prior quarter.
Across five years, Long-Term Debt Repayments topped out at $15.0 million in Q3 2020 and bottomed at -$62000.0 in Q2 2020.